ILMN- NAS (USA) Also traded in: Austria, Brazil, Germany, Mexico, UK
Illumina Inc Ordinary Shares

Currently 3/5

Business Predictability Rank: 3-Star
Back Testing Results:
Average gain of all 3-Star stocks: 8.2% per year.
% of Stocks that are in still loss if held for 10yrs: 11%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$233.74

0.18(0.08%) Volume: 1,458,578 9:08PM EDT

Avg Vol (1m): 965,903

Warning! GuruFocus has detected 2 Severe Warning Signs with NAS:ILMN. Click here to check it out.

Market Cap : 36.72 B	Enterprise Value : 37.89 B	PE Ratio : 50.80	PB Ratio : 3.37

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Switch to:

中文

Illumina Institutional Ownership

: 80.78% (As of Today)

View and export this data going back to 2000. Start your Free Trial

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Illumina's institutional ownership is 80.78%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Illumina's Insider Ownership is 1.92%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Illumina's Float Percentage Of Total Shares Outstanding is 86.83%.

Illumina Institutional Ownership Historical Data

The historical data trend for Illumina's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Historical Data

The historical data trend for Illumina can be seen below:

	2021-07-31	2021-08-31	2021-09-30	2021-10-31	2021-11-30	2021-12-31	2022-01-31	2022-02-28	2022-03-31	2022-04-30
Institutional Ownership	94.53	88.27	87.58	83.76	83.85	82.88	82.28	82.16	81.38	80.78

Illumina Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Illumina Business Description

Industry

Healthcare » Medical Diagnostics & Research NAICS : 621511 SIC : 8071

Comparable Companies

XSWX:LONN SHSE:603259 NYSE:IQV NAS:IDXX NYSE:A NYSE:MTD NYSE:LH NYSE:PKI XPAR:ERF NAS:ICLR

Traded in Other Exchanges

ILMN:Mexico 0J8Z:UK ILU:Germany ILU:Germany ILU:Germany I1LM34:Brazil ILMN:Austria

Address

5200 Illumina Way, San Diego, CA, USA, 92122

Website

https://www.illumina.com

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.

Executives

Flatley Jay T	director	9885 TOWNE CENTRE DR SAN DIEGO CA 92121
Tousi Susan H	officer: SVP Product Development	5200 ILLUMINA WAY SAN DIEGO CA 92122
Reeves Kathryne Gambrell	officer: SVP, Chief Marketing Officer	5200 ILLUMINA WAY SAN DIEGO CA 92122
Goswami Joydeep	officer: SVP Corp Business Development	SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023
Dadswell Charles	officer: SVP & General Counsel	5200 ILLUMINA WAY SAN DIEGO CA 92122
Desouza Francis A	director, officer: President and CEO	350 ELLIS STREET MOUNTAIN VIEW CA 94043
Van Oene Mark	officer: SVP Chief Commercial Officer	5200 ILLUMINA WAY SAN DIEGO CA 92122
Ragusa Robert P	officer: SVP, Global Quality & Ops	PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Mcginnis Karen K	officer: VP, Chief Accounting Officer	INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284
Hoyt Aimee L	officer: SVP, Chief People Officer	5200 ILLUMINA WAY SAN DIEGO CA 92122
Ronaghi Mostafa	officer: SVP, Entrepreneurial Devlopmt	9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
Aravanis Alexander	officer: SVP, Chief Technology Officer	5200 ILLUMINA WAY SAN DIEGO CA 92122
Siegel Susan E	director	3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025
Thompson John Wendell	director	C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053
Epstein Robert S	director	PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}

Illumina Headlines

From GuruFocus

Financial Consulate, Inc Buys iShares J.P. Morgan EM Corporate Bond ETF, Exxon Mobil Corp, Royalty Pharma PLC, Sells Invesco S&P 500 Equal Weight Financials ETF, Vanguard S&P 500 ETF, CrowdStrike Holdings Inc

By insider 02-07-2022

Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference

By PRNewswire 01-10-2022

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us 中文
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

GuruFocus Screeners

My Screeners

Value Screens

Model Portfolios

Market Data

Economic Indicators

By Country

Articles

Submit Articles

Illumina Institutional Ownership

Illumina Institutional Ownership Historical Data

Illumina Institutional Ownership Calculation

Illumina Business Description

Illumina Headlines

Vontobel Holding Ltd. Buys Illumina Inc, Sells Intuitive Surgical Inc, Arista Networks Inc, InMode

Illumina Supports Norway's Pioneering Precision Medicine Study

Illumina Enters Co-Development Partnership with SomaLogic

Illumina To Webcast Upcoming Investor Conferences

Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care

Financial Consulate, Inc Buys iShares J.P. Morgan EM Corporate Bond ETF, Exxon Mobil Corp, Royalty Pharma PLC, Sells Invesco S&P 500 Equal Weight Financials ETF, Vanguard S&P 500 ETF, CrowdStrike Holdings Inc

Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference

Illumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia

Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe

Illumina To Webcast Upcoming Investor Conference

OTR Global Upgrades Illumina (ILMN) to Buy

$ILMN - Illumina, Inc. (ILMN) CEO Francis deSouza Presents at Cowen Health Care Conference (Transcript).…

Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics

Why Illumina Stock Just Jumped 9.5%

Illumina (ILMN) to Address Nasopharynx Cancer With New Pact

Illumina (ILMN) was Upgraded to a Hold Rating at Credit Suisse

How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener

Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing

Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates

Company News for Jan 12, 2022

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Illumina (ILMN) Invests in Seven Additional Genomics Startups

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View